Experience of first- and subsequent-line systemic therapy in the treatment of non-small cell lung cancer

Therapeutic Advances in Medical Oncology

Volumn 3, Issue 4, 2011, Pages 163-170

  Eccles, B K ^a   Geldart, T R ^a   Laurence, V M ^b   Bradley, K L ^b   Lwin, M T ^b  

^a ROYAL BOURNEMOUTH HOSPITAL   (United Kingdom)

^b POOLE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

non small cell lung cancer; retrospective analysis; systemic therapy

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ERLOTINIB; GEMCITABINE; NAVELBINE; PEMETREXED; THALIDOMIDE; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER STAGING; CANCER THERAPY; CLINICAL PRACTICE; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; SYSTEMIC THERAPY; TREATMENT RESPONSE; UNITED KINGDOM;

EID: 79960079183     PISSN: 17588340     EISSN: 17588359     Source Type: Journal    
DOI: 10.1177/1758834011409096     Document Type: Article

References (16)

1. Azzoli, C.G., Baker, S., Jr, Temin, S., Pao, W., Aliff, T., Brahmer, J., et al. (2009) American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small Cell Lung Cancer. J Clin Oncol 27: 6251-6266. Available at: http://www.asco.org/guidelines/nsclc.
2. Cancer Research UK (2010) Cancer research UK mortality statistics, July 2010, http://info.cancerresearchuk.org/cancerstats/mortality/.
3. Cappuzzo F. Ciuleanu T. Stelmakh L. Cicenas S. Szczésna A. Juhász E. et al (2010) Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 11: 521–529.
4. Ciuleanu T. Brodowicz T. Zielinski C. Kim J.H. Krzakowski M. Laack E. et al (2009) Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 374: 1432–1440.
5. de Marinis F. Grossi F. (2008) Clinical evidence for second- and third-line treatment options in advanced non-small cell lung cancer. The Oncologist 13(Suppl. 1): 14–20.
6. Fidias P.M. Dakhil S.R. Lyss A.P. Loesch D.M. Waterhouse D.M. Bromund J.L. et al (2009) Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small cell lung cancer. J Clin Oncol 27: 591–598.
7. Gow C.-H. Chang Y.-L. Hsu Y.-C. Tsai M.-F. Wu C.-T. Yu C.-J. et al (2009) Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naïve non-small-cell lung cancer. Ann Oncol 20: 696–702.
8. Inoue A. Kobayashi K. Usui K. Maemondo M. Okinaga S. Mikami I. et al (2009) First-line gefitinib for patients with advanced non–small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol 27: 1394–1400.
9. Maemondo M. Inoue A. Kobayashi K. Sugawara S. Oizumi S. Isobe H. et al (2010) Gefitinib or chemotherapy for non–small-cell lung cancer with mutated EGFR. N Engl J Med 362: 25–26.
10. Massarelli E. Andre F. Liu D.D. Lee J.J. Wolf M. Fandi A. et al (2003) A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer. Lung Cancer 39: 55–61.
11. Mok T.S. Wu Y.-L. Thongprasert S. Yang C.-H. Chu D.T. Saijo N. et al (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361: 947–957.
12. Rudd R. Gower N. Spiro S. Eisen T.G. Harper P.G. Littler J.A.H. et al (2005) Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small-cell lung cancer: a phase III randomized study of the London Lung Cancer Group. J Clin Oncol 23: 142–153.
13. Scagliotti G.V. Parikh P. von Pawel J. Biesma B. Vansteenkiste J. Manegold C. et al (2008) Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemextrexed in chemotherapy-naïve patients with advanced–stage non-small cell lung cancer. J Clin Oncol 26: 3543–3551.
14. Schiller J.H. Harrington D. Belani C.P. Langer C. Sandler A. Krook J. et al (2002) Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 346: 92–98.
15. Shepherd F.A. Rodrigues Pereira J. Ciuleanu T. Tan E.H. Hirsh V. Thongprasert S. et al (2005) Erlotinib in previously treated non-small-cell-lung cancer. N Engl J Med 353: 123–132.
16. Tambo Y. Kasahara K. Kimura H. Sone T. Araya T. Tamori S. et al (2007) A retrospective study of salvage chemotherapy for advanced non-small cell lung cancer; the efficacy of third and fourth chemotherapy: P2-312. J Thoracic Oncol 2: S697–S697.